In vitro diagnosis of T cell-mediated drug allergy

Clinical and Experimental Allergy

Volumn 41, Issue 4, 2011, Pages 461-470

  Porebski, G ^a   Gschwend Zawodniak, A ^a   Pichler, W J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; GAMMA INTERFERON; GRANULYSIN; GRANZYME B; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 5; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1;

ALLERGY TEST; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC TEST; DRUG HYPERSENSITIVITY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS;

DRUG HYPERSENSITIVITY; HUMANS; IMMUNOLOGIC TECHNIQUES; T-LYMPHOCYTES;

EID: 79952608571     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03701.x     Document Type: Review

References (89)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200-5.
2. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 2004; 329:15-9.
3. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23:483-507.
4. Hunziker T, Bruppacher R, Kuenzi UP et al. Classification of ADR: a proposal for harmonization and differentiation based on the experience of the comprehensive hospital drug monitoring Bern/St. Gallen, 1974-1993. Pharmacoepidemiol Drug Saf 2002; 11:159-63.
5. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139:683-9.
6. Coombs PR, Gell PG. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell RR, ed. Clinical aspects of immunology. Oxford: Oxford University Press, 1968; 575-96.
7. Romano A, Blanca M, Torres MJ et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004; 59:1153-60.
8. Padial A, Antunez C, Blanca-Lopez N et al. Non-immediate reactions to betalactams: diagnostic value of skin testing and drug provocation test. Clin Exp Allergy 2008; 38:822-8.
9. Bousquet PJ, Pipet A, Bousquet-Rouanet L, Demoly P. Oral challenges are needed in the diagnosis of beta-lactam hypersensitivity. Clin Exp Allergy 2008; 38:185-90.
10. Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004; 140:1001-6.
11. Aberer W, Bircher A, Romano A et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58:854-63.
12. Spanou Z, Keller M, Britschgi M et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 2006; 17:2919-27.
13. Mennicke M, Zawodniak A, Keller M et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant 2009; 9:2197-202.
14. Luque I, Leyva L, José Torres M et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001; 56:611-8.
15. Beeler A, Engler O, Gerber BO, Pichler WJ. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 2006; 117:455-62.
16. Naisbitt DJ, Farrell J, Wong G et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111:1393-403.
17. Yawalkar N, Hari Y, Frutig K et al. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000; 115:647-52.
18. Hari Y, Frutig-Schnyder K, Hurni M et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001; 31:1398-408.
19. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62:1439-44.
20. Lochmatter P, Zawodniak A, Pichler WJ. In vitro tests in drug hypersensitivity diagnosis. Immunol Allergy Clin North Am 2009; 29:537-54.
21. Song A, Nikolcheva T, Krensky AM. Transcriptional regulation of RANTES expression in T lymphocytes. Immunol Rev 2000; 177:236-45.
22. Ullman KS, Northrop JP, Verweij CL, Crabtree GR. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol 1990; 8:421-52.
23. Ortiz BD, Nelson PJ, Krensky AM. Switching gears during T-cell maturation: RANTES and late transcription. Immunol Today 1997; 18:468-71.
24. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-85.
25. Stepp SE, Mathew PA, Bennett M, de Saint Basile G, Kumar V. Perforin: more than just an effector molecule. Immunol Today 2000; 21:254-6.
26. Posadas SJ, Padial A, Torres MJ et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109:155-61.
27. Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14:1343-50.
28. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30:847-55.
29. Nassif A, Bensussan A, Boumsell L et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114:1209-15.
30. Le Cleach L, Delaire S, Boumsell L et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119:225-30.
31. Schmid S, Kuechler PC, Britschgi M et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol 2002; 161:2079-86.
32. Kuechler PC, Britschgi M, Schmid S, Hari Y, Grabscheid B, Pichler WJ. Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy 2004; 59:613-22.
33. Schnyder B, Frutig K, Mauri-Hellweg D et al. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazole-induced skin reaction. Clin Exp Allergy 1998; 28:1412-7.
34. Chaves P, Torres MJ, Aranda A et al. Natural killer-dendritic cell interaction in lymphocyte responses in hypersensitivity reactions to betalactams. Allergy 2010; 65:1600-8.
35. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-3.
36. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7:813-8.
37. Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.
38. *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-32.
39. Brunner KT, Mauel J, Cerottini JC et al. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 1968; 14:181-96.
40. Liu L, Chahroudi A, Silvestri G et al. Visualization and quantification of T cell mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med 2002; 8:185-9.
41. Sheehy ME, McDermott AB, Furlan SN et al. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 2001; 249:99-110.
42. Rozieres A, Hennino A, Rodet K et al. Detection and quantification of drug-specific T cells in penicillin allergy. Allergy 2009; 64:534-42.
43. Zawodniak A, Lochmatter P, Yerly D et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy 2010; 65:376-84.
44. Rininsland FH, Helms T, Asaad RJ, Boehm BO, Tary-Lehmann M. Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods 2000; 240:143-55.
45. van Besouw NM, Zuijderwijk JM, de Kuiper P, Ijzermans JN, Weimar W, van der Mast BJ. The granzyme B and interferon-gamma enzyme-linked immunospot assay as alternatives for cytotoxic T-lymphocyte precursor frequency after renal transplantation. Transplantation 2005; 79:1062-6.
46. 8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78.
47. Boon AC, de Mutsert G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Functional profile of human influenza virus-specific cytotoxic T lymphocyte activity is influenced by interleukin-2 concentration and epitope specificity. Clin Exp Immunol 2005; 142:45-52.
48. Shafer-Weaver K, Rosenberg S, Strobl S, Gregory Alvord W, Baseler M, Malyguine A. Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials. J Immunother 2006; 29:328-35.
49. Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 2009; 151:514-5.
50. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997; 27:175-81.
51. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59:809-20.
52. Britschgi M, Steiner UC, Schmid S et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107:1433-41.
53. Hertl M, Geisel J, Boecker C et al. Selective generation of CD81 T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br J Dermatol 1993; 128:619-26.
54. Mauri-Hellweg D, Bettens F, Mauri D et al. Activation of drug-specific CD41 and CD81 T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155:462-72.
55. Straumann A, Bauer M, Pichler WJ et al. Acute pancreatitis due to pyritinol: an immune-mediated phenomenon. Gastroenterology 1998; 115:452-4.
56. Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997; 41:534-40.
57. Tsutsui H, Terano Y, Sakagami C et al. Drug-specific T cells derived from patients with drug-induced allergic hepatitis. J Immunol 1992; 149:706-16.
58. Osterwalder P, Koch J, Wuthrich B et al. Intermittent fever of unknown origin. Dtsch Med Wochenschr 1998; 123:761-5 (in German).
59. Berger D, Pichler W, Savic S et al. Fever pneumonia and eosinophilia. Praxis 2007; 96:1543-7 (in German).
60. Neukomm CB, Yawalkar N, Helbling A et al. T-cell reactions to drugs in distinct clinical manifestations of drug allergy. J Investig Allergol Clin Immunol 2001; 11:275-84.
61. Warrington RJ, Tse KS. Lymphocyte transformation studies in drug hypersensitivity. Can Med Assoc J 1979; 120:1089-94.
62. Barna BP, Gogate P, Deodhar SD, Moeder M. Lymphocyte transformation and radioallergosorbent tests in drug hypersensitivity. Am J Clin Pathol 1980; 73:172-6.
63. Berg PA, Brattig N, Diao G-J et al. Diagnose arzneimittelbedingter Nebenwirkungen mit Hilfe des Lyphozytentransformationstests. Allergologie 1983; 6:77-81 (in German).
64. Schnyder B, Pichler WJ. Skin and laboratory tests in amoxicillin- and penicillin-induced morbilliform skin eruption. Clin Exp Allergy 2000; 30:590-5.
65. Naisbitt DJ, Britschgi M, Wong G et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003; 63:732-41.
66. Beeler A, Pichler WJ. In vitro tests of T cell mediated drug hypersensitivity. Expert Rev Clin Immunol 2006; 2:887-900.
67. Cornejo-Garcia JA, Fernandez TD, Torres MJ et al. Differential cytokine and transcription factor expression in patients with allergic reactions to drugs. Allergy 2007; 62:1429-38.
68. Posadas SJ, Leyva L, Torres MJ et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol 2000; 106:769-76.
69. Gaspard I, Guinnepain MT, Laurent J et al. Il-4 and IFN-gamma mRNA induction in human peripheral lymphocytes specific for beta-lactam antibiotics in immediate or delayed hypersensitivity reactions. J Clin Immunol 2000; 20:107-16.
70. Lochmatter P, Beeler A, Kawabata TT, Gerber BO, Pichler WJ. Drug-specific in vitro release of IL-2, IL-5, IL-13 and IFN-gamma in patients with delayed-type drug hypersensitivity. Allergy 2009; 64:1269-78.
71. Brander C, Mauri-Hellweg D, Bettens F et al. Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol 1995; 155:2670-8.
72. Brugnolo F, Annunziato F, Sampognaro S et al. Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions. J Immunol 1999; 163:1053-9.
73. Halevy S, Cohen AD, Grossman N. Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymphocytes in cutaneous adverse drug reactions. J Am Acad Dermatol 2005; 52:254-61.
74. Posadas SJ, Torres MJ, Mayorga C et al. Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs. Blood Cells Mol Dis 2002; 29:179-89.
75. Tsuge I, Okumura A, Kondo Y et al. Allergen-specific T-cell response in patients with phenytoin hypersensitivity; simultaneous analysis of proliferation and cytokine production by carboxyfluorescein succinimidyl ester (CFSE) dilution assay. Allergol Int 2007; 56:149-55.
76. Khalil G, El-Sabban M, Al-Ghadban S et al. Cytokine expression profile of sensitized human T lymphocytes following in vitro stimulation with amoxicillin. Eur Cytokine Netw 2008; 19:131-41.
77. Yawalkar N, Shrikhande M, Hari Y et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106:1171-6.
78. Sachs B, Erdmann S, Al-Masaoudi T et al. In vitro drug allergy detection system incorporating human liver microsomes in clorazepate-induced skin rash: drugspecific proliferation associated with interleukin-5 secretion. Br J Dermatol 2001; 144:316-20.
79. Sachs B, Erdmann S, Malte Baron J et al. Determination of interleukin-5 secretion from drug-specific activated ex vivo peripheral blood mononuclear cells as a test system for the in vitro detection of drug sensitization. Clin Exp Allergy 2002; 32:736-44.
80. Merk HF. Diagnosis of drug hypersensitivity: lymphocyte transformation test and cytokines. Toxicology 2005; 209:217-20.
81. Martin M, Wurpts G, Ott H et al. In vitro detection and characterization of drug hypersensitivity using flow cytometry. Allergy 2010; 65:32-9.
82. Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2002; 2:325-31.
83. Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ. CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy 2008; 63:181-8.
84. Torres MJ, Mayorga C, Cornejo-Garcia JA et al. Monitoring non-immediate allergic reactions to iodine contrast media. Clin Exp Immunol 2008; 152:233-8.
85. Nishio D, Izu K, Kabashima K et al. T cell populations propagating in the peripheral blood of patients with drug eruptions. J Dermatol Sci 2007; 48:25-33.
86. Rodriguez-Pena R, Lopez S, Mayorga C et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams. J Allergy Clin Immunol 2006; 118:949-56.
87. Martin SF, Esser PR, Schmucker S et al. T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Cell Mol Life Sci 2010; 67:4171-84.
88. 25+ cells allows for the sensitive in vitro screening of contact allergens. J Invest Dermatol 2008; 128:2119-22.
89. Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182:8071-9.